Study of INCB123667 in Subjects With Advanced Solid Tumors

Active:	Yes
Cancer Type:	Esophogeal Cancer Gynecologic Cancers Ovarian Cancer Primary Peritoneal Cancer Stomach/ Gastric Cancer	NCT ID:	NCT05238922
Trial Phases:	Phase I	Protocol IDs:	INCB 123667-101 (primary) NCI-2022-03370
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Incyte Corporation
NCI Full Details:	http://clinicaltrials.gov/show/NCT05238922

Summary

This is an open-label, dose-escalation and dose-expansion study to determine the safety,
tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when
administered as monotherapy and in combination with anticancer therapies in participants
with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In
Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be
administered in combination with anticancer therapies of interest. Each part will
comprise a dose escalation portion (Parts 1a and 2a, respectively) and a dose-expansion
portion (Parts 1b and 2b, respectively).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.